Gastric cancer
Conditions
Interventions
Oral administration of Rikkunshito 7.5g per day for 84 days from post operative day three.
No oral administration of Rikkunshito perioperatively.
Sponsors
Jichi Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Histological proven adenocarcinoma of stomach 2. cT1-T4a and no distant metastasis 3. R0 resection with total gastrectomy 4. Age 20-80 years 5. Eastern Cooperative Oncology Group performance status 0-1 6. Normal function of organ systems 7. Written informed consent
Exclusion criteria
Exclusion criteria: 1. Synchronous or metachronous cancer 2. Reduced oral intake 3. Past gastrointestinal surgery 4. Preoperative chemotherapy 5. Administration of Rikkunshito ingredients before surgery 6. Unstable angina or myocardial infarction within six months 7. Pulmonary disease treated with continuous oxygen 8. Hemorrhagic tendency 9. Diabetes mellitus 10. Systemic treatment with corticosteroids 11. Pregnancy, breast-feeding, or contemplating pregnancy. 12. Mental disorder that affects informed consent or study protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Weight loss at three months after surgery | — |
Secondary
| Measure | Time frame |
|---|---|
| Medication compliance of Rikkunshito Adverse events associated with Rikkunshito Quality of life score Plasma glucagon-like peptide-1 | — |
Countries
Japan
Contacts
Public ContactYoshinori Hosoya
Jichi Medical University Hospital Department of Surgery
Outcome results
None listed